Brigatinib
Metastatic Malignant Neoplasm in the Central Nervous System
Sameek RoychowdhurySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Metastatic Malignant Neoplasm in the Central Nervous System cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CBL-0137 FREE BASE Children's Oncology Group | Phase 1/2 | CC |
wsd0922-fu Mayo Clinic | Phase 1 | CC |
Dabrafenib Mayo Clinic | Phase 1 | CC |
E-6201 Mayo Clinic | Phase 1 | D |
Same molecule, other indications
Brigatinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →